"Fluticasone furoate" - PMC

Result Filters

You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 1733

<< First< Prev

Page of 87

Next >Last >>

Select item 37793131.

The Relationship Between Fluticasone Furoate Systemic Exposure and Cortisol Suppression

Ann Allen

Clin Pharmacokinet. 2013; 52(10): 885–896. Published online 2013 May 30. doi: 10.1007/s40262-013-0078-1

PMCID:: PMC3779313

Article PDF–477K

Select item 94027262.

Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis

Afisi S. Ismaila, Katrin Haeussler, Alexandrosz Czira, Ji-Hee Youn, Mia Malmenäs, Nancy A. Risebrough, Jatin Agarwal, Maria Nassim, Raj Sharma, Chris Compton, Claus F. Vogelmeier, MeiLan K. Han, David M. G. Halpin

Adv Ther. 2022; 39(9): 3957–3978. Published online 2022 Jul 17. doi: 10.1007/s12325-022-02231-0

PMCID:: PMC9402726

Article PDF–2.1M

Select item 61750983.

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD

Rashmi Mehta, Eleni Pefani, Misba Beerahee, Noushin Brealey, Helen Barnacle, Ruby Birk, Chang‐Qing Zhu, David A. Lipson

J Clin Pharmacol. 2018 Nov; 58(11): 1461–1467. Published online 2018 May 15. doi: 10.1002/jcph.1253

PMCID:: PMC6175098

Article PDF–824K

Select item 51198454.

Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease

Sarah Siederer, Ann Allen, Shuying Yang

Eur J Drug Metab Pharmacokinet. 2016; 41(6): 743–758. Published online 2015 Oct 16. doi: 10.1007/s13318-015-0303-4

PMCID:: PMC5119845

Article PDF–1.7M

Select item 69959875.

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

Rashmi Mehta, Colm Farrell, Siobhán Hayes, Ruby Birk, Malek Okour, David A. Lipson

Clin Pharmacokinet. 2020; 59(1): 67–79. Published online 2019 Jul 19. doi: 10.1007/s40262-019-00794-w

PMCID:: PMC6995987

Article PDF–1.8M

Select item 51220186.

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma

Paul M. O’Byrne, Loretta Jacques, Caroline Goldfrad, Namhee Kwon, Michael Perrio, Louisa J. Yates, William W. Busse

Respir Res. 2016; 17: 157. Published online 2016 Nov 24. doi: 10.1186/s12931-016-0473-x

PMCID:: PMC5122018

Article PDF–690K

Select item 59416627.

Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects

Mario Malerba, Matteo Nardin, Giuseppe Santini, Nadia Mores, Alessandro Radaeli, Paolo Montuschi

Ther Adv Respir Dis. 2018 Jan-Dec; 12: 1753466618760779. Published online 2018 Mar 14. doi: 10.1177/1753466618760779

PMCID:: PMC5941662

Article PDF–577K

Select item 105974278.

Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19

David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart, Adrian F. Hernandez, Sean Collins, Matthew William McCarthy, Dushyantha Jayaweera, Nina Gentile, Mario Castro, Mark Sulkowski, Kathleen McTigue, G. Michael Felker, Adit A. Ginde, Sarah E. Dunsmore, Stacey J. Adam, Allison DeLong, George Hanna, April Remaly, Florence Thicklin, Rhonda Wilder, Sybil Wilson, Elizabeth Shenkman, Susanna Naggie

N Engl J Med. 2023 Sep 21; 389(12): 1085–1095. doi: 10.1056/NEJMoa2209421

PMCID:: PMC10597427

Article PDF–757K

Select item 104275469.

Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management

Peter Daley-Yates, Dave Singh, Juan M. Igea, Luigi Macchia, Manish Verma, Norbert Berend, Maximilian Plank

Adv Ther. 2023; 40(9): 4042–4059. Published online 2023 Jul 12. doi: 10.1007/s12325-023-02585-z

Correction in:: Adv Ther. 2023; 40(12): 5596–5597.

PMCID:: PMC10427546

Article PDF–1003K

Select item 779836510.

Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial

Francois Maltais, Isabelle Schenkenberger, Pascal L. M. L. Wielders, Juan Ortiz de Saracho, Kenneth Chinsky, Michael Watkins, Valerie Millar, Courtney Crim

Ther Adv Respir Dis. 2020 Jan-Dec; 14: 1753466620965145. Published online 2020 Oct 20. doi: 10.1177/1753466620965145

PMCID:: PMC7798365

Article PDF–769K

Select item 369342811.

Fluticasone Furoate, a Novel Inhaled Corticosteroid, Demonstrates Prolonged Lung Absorption Kinetics in Man Compared with Inhaled Fluticasone Propionate

Ann Allen, Philippe J. Bareille, Vicki M. Rousell

Clin Pharmacokinet. 2013; 52(1): 37–42. Published online 2012 Nov 27. doi: 10.1007/s40262-012-0021-x

PMCID:: PMC3693428

Article PDF–444K

Select item 395272112.

A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects

Rodger Kempsford, Ann Allen, Kathryn Kelly, Parminder Saggu, Courtney Crim

Br J Clin Pharmacol. 2014 Mar; 77(3): 466–479. Published online 2014 Feb 21. doi: 10.1111/bcp.12243

PMCID:: PMC3952721

Article PDF–1.4M

Select item 948710813.

Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial

Peter Daley-Yates, Brian Keppler, Amanda Baines, George Bardsley, James Fingleton

Respir Res. 2022; 23: 258. Published online 2022 Sep 20. doi: 10.1186/s12931-022-02164-w

PMCID:: PMC9487108

Article PDF–1.5M

Select item 824923714.

Intranasal fluticasone furoate in pediatric allergic rhinitis: randomized controlled study

Yamei Zhang, Ping Wei, Bobei Chen, Xiaoyan Li, Xianyang Luo, Xianming Chen, Mingliang Xiang, Lan Li, Sijun Zhao, Xuping Xiao, Xinmin Yang, Jie Chen, Yong Fu, Shuifang Xiao, Haixia Liu, Lei Cheng, Hongbing Yao

Pediatr Res. 2021; 89(7): 1832–1839. Published online 2020 Oct 2. doi: 10.1038/s41390-020-01180-0

PMCID:: PMC8249237

Article PDF–647K

Select item 759599315.

24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study

David A. Lipson, Ruby Birk, Noushin Brealey, Chang-Qing Zhu

Adv Ther. 2020; 37(12): 4894–4909. Published online 2020 Oct 3. doi: 10.1007/s12325-020-01496-7

PMCID:: PMC7595993

Article PDF–1.8M

Select item 469033016.

Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials

Annette S. Gross, Caroline Goldfrad, Soichiro Hozawa, Mark H. James, Christine S. Clifton, Yutaro Sugiyama, Loretta Jacques

BMC Pulm Med. 2015; 15: 165. Published online 2015 Dec 24. doi: 10.1186/s12890-015-0159-z

PMCID:: PMC4690330

Article PDF–601K

Select item 727545717.

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Nicola C. Day, Subramanya Kumar, Gerard Criner, Mark Dransfield, David M. G. Halpin, MeiLan K. Han, C. Elaine Jones, Morrys C. Kaisermann, Sally Kilbride, Peter Lange, David A. Lomas, Neil Martin, Fernando J. Martinez, Dave Singh, Robert Wise, David A. Lipson

Respir Res. 2020; 21: 139. Published online 2020 Jun 5. doi: 10.1186/s12931-020-01398-w

PMCID:: PMC7275457

Article PDF–800K

Select item 658570718.

Open‐Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently

Claire Ambery, Graeme Young, Teresa Fuller, Alex Georgiou, David Ramsay, Adeep Puri, Peter Daley‐Yates

Clin Pharmacol Drug Dev. 2019 Feb-Mar; 8(2): 188–197. Published online 2018 Aug 2. doi: 10.1002/cpdd.603

PMCID:: PMC6585707

Article PDF–588K

Select item 730173819.

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

David A. Lipson, Courtney Crim, Gerard J. Criner, Nicola C. Day, Mark T. Dransfield, David M. G. Halpin, MeiLan K. Han, C. Elaine Jones, Sally Kilbride, Peter Lange, David A. Lomas, Sally Lettis, Pamela Manchester, Neil Martin, Dawn Midwinter, Andrea Morris, Steven J. Pascoe, Dave Singh, Robert A. Wise, , on behalf of the IMPACT Investigators

Am J Respir Crit Care Med. 2020 Jun 15; 201(12): 1508–1516. Published online 2020 Jun 15. doi: 10.1164/rccm.201911-2207OC

PMCID:: PMC7301738

Article PDF–826K

Select item 433942220.

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy

Gillian Stynes, Henrik Svedsater, Jaro Wex, Sally Lettis, David Leather, Emanuela Castelnuovo, Michelle Detry, Scott Berry

Respir Res. 2015; 16(1): 25. Published online 2015 Feb 15. doi: 10.1186/s12931-015-0184-8

PMCID:: PMC4339422

Article PDF–646K

<< First< Prev

Page of 87

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

PMC Images search for "Fluticasone furoate"

Fig. 3

Fraction (%) of inhaled fluticasone furoate (2,000 μg) and fluticasone propionate (1,000 μg) absorbed from the lung. FF fluticasone furoate, FP fluticasone propionate

Fluticasone Furoate, a Novel Inhaled Corticosteroid, Demonstrates Prolonged Lung Absorption Kinetics in Man Compared with Inhaled Fluticasone Propionate

Clin Pharmacokinet. 2013;52(1):37-42.
Figure 2

Fluticasone furoate chemical structure.

Fluticasone furoate nasal spray in the treatment of allergic rhinitis

Ther Clin Risk Manag. 2008 Apr;4(2):465-472.
Fig. 2

Mean (± SD) concentration–time profile following inhaled fluticasone furoate (2,000 μg) and fluticasone propionate (1,000 μg) administration. FF fluticasone furoate, FP fluticasone propionate, LLQ lower limit of quantitation

Fluticasone Furoate, a Novel Inhaled Corticosteroid, Demonstrates Prolonged Lung Absorption Kinetics in Man Compared with Inhaled Fluticasone Propionate

Clin Pharmacokinet. 2013;52(1):37-42.
Fig. 1

Mean (±SD) plasma concentration–time profile following 250 μg single intravenous fluticasone furoate and fluticasone propionate administration. FF fluticasone furoate, FP fluticasone propionate, IV intravenous, LLQ lower limit of quantitation

Fluticasone Furoate, a Novel Inhaled Corticosteroid, Demonstrates Prolonged Lung Absorption Kinetics in Man Compared with Inhaled Fluticasone Propionate

Clin Pharmacokinet. 2013;52(1):37-42.